Ablynx and BI enter 10-target Nanobody deal
Therapeutic antibody developer Ablynx has entered into a new deal with Boehringer Ingelheim for the discovery, development, and commercialization of up to 10 therapeutics incorporating Ablynx's Nanobody technology.
- Large Molecule
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com